Home » Topics » BioWorld Science

BioWorld Science
RSS

Argenx reports cohort 1 interim data from phase II study of efgartigimod in pemphigus vulgaris

June 20, 2018

Clinical benefit noted with NIR-178 in patients with non-small cell lung cancer

June 20, 2018

Tumor mutations can aid variant calling for germline

June 20, 2018

Idorsia initiates phase III study of aprocitentan for resistant hypertension

June 20, 2018

Kala updates registration plan for KPI-121 for short-term treatment of dry eye disease

June 20, 2018

Can-Fite updates status of phase II trial of namodenoson in advanced HCC

June 20, 2018

Seattle Children's initiates phase I trial of CAR T-cell therapy for pediatric CNS tumors

June 20, 2018

Monalizumab shows promising activity in combination with durvalumab in MSS-CRC

June 20, 2018

Andes-1537 well tolerated in phase I study, dose expansions planned

June 20, 2018

Genentech, Roche and Paraza Pharma patent TRPA1 antagonists

June 20, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...